Spots Global Cancer Trial Database for primary myelofibrosis (pmf)
Every month we try and update this database with for primary myelofibrosis (pmf) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) | NCT03136185 | Myelofibrosis Post-polycythem... Post-essential ... Primary Myelofi... | Bomedemstat | 18 Years - | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | NCT02718300 | MPN (Myeloproli... | Parsaclisib Parsaclisib Ruxolitinib Parsaclisib Parsaclisib | 18 Years - | Incyte Corporation | |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03755518 | Primary Myelofi... Post-Polycythem... Myelofibrosis Post-essential ... | FEDRATINIB | 18 Years - | Celgene | |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | NCT02515630 | Primary Myelofi... Post-polycythem... Postessential T... | MMB | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases | NCT00910728 | Primary Myelofi... Post-Polycythae... Essential Throm... | AZD1480 | 25 Years - 99 Years | AstraZeneca | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | NCT03662126 | Primary Myelofi... Post-Polycythem... Post-Essential ... | KRT-232 Best Available ... | 18 Years - | Kartos Therapeutics, Inc. | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis | NCT04217993 | Primary Myelofi... Post-polycythem... Post-essential ... | Jaktinib hydroc... | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | NCT04878003 | Primary Myelofi... Post-Polycythem... Post-Essential ... | KRT-232 TL-895 | 18 Years - | Kartos Therapeutics, Inc. | |
| Extended Access of Momelotinib in Adults With Myelofibrosis | NCT03441113 | Neoplasms Post-polycythem... Primary Myelofi... Post-essential ... | MMB | 18 Years - | GlaxoSmithKline | |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | NCT02515630 | Primary Myelofi... Post-polycythem... Postessential T... | MMB | 18 Years - | Sierra Oncology LLC - a GSK company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
